预测贝伐单抗治疗晚期结直肠癌疗效的研究进展
摘要
结直肠癌是人类最常见的恶性肿瘤之一,目前贝伐单抗联合化疗治疗晚期直肠癌已经广泛应用于临床,但目前临床中有效预测该药物疗效的因素尚未确定。本文就在临床中研究预测贝伐单抗治疗晚期结直肠癌疗效的进展作一综述。
引文
[1]Aljehani MA,Morgan JW,Guthrie LA,et al.Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer[J].JAMA Surg,2018,153(1):60-67.
[2]Chen W,Sun K,Zheng R,et al.Cancer incidence and mortality in China,2014[J].Chin J Cancer Res,2018,30(1):1-12.
[3]Boisen MK,Johansen JS,Dehlendorff C,et al.Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer[J].Ann Oncol,2013,24(10):2554-2559.
[4]Loupakis F,Yang D,Yau L,et al.Primary tumor location as a prognostic factor in metastatic colorectal cancer[J].J Natl Cancer Inst,2015,107(3).
[5]Anastasiou D,Poulogiannis G,Asara JM,et al.Inhibition of pyruvate kinase M2by reactive oxygen species contributes to cellular antioxidant responses[J].Scie nce,2011,334(6060):1278-1283.
[6]Azuma M,Shi M,Danenberg KD,et al.Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients[J].Pharmacogenomics,2007,8(12):1705-1713.
[7]Yin C,Jiang C,Liao F,et al.Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer[J].Onco Targets Ther,2014,7:1415-1422.
[8]Zhang CJ,Zhang SY,Zhang CD,et al.Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer:an updated metaanalysis[J].Aging(Albany NY),2018,10(6):1424-1441.
[9]Amadori M,Barone D,Scarpi E,et al.Dynamic contrast-enhanced ultrasonography(D-CEUS)for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer[J].Eur Radiol,2018,28(7):2969-2978.
[10]De Bruyne S,Van Damme N,Smeets P,et al.Value of DCE-MRIand FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases[J].Br JCancer,2012,106(12):1926-1933.
[11]Holch JW,Ricard I,Stintzing S,et al.Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab(FIRE-3 trial)[J].Eur JCancer,2019,106:115-125.
[12]Prager GW,Braemswig KH,Martel A,et al.Baseline carcinoembryonic antigen(CEA)serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer[J].Cancer Sci,2014,105(8):996-1001.
[2]Chen W,Sun K,Zheng R,et al.Cancer incidence and mortality in China,2014[J].Chin J Cancer Res,2018,30(1):1-12.
[3]Boisen MK,Johansen JS,Dehlendorff C,et al.Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer[J].Ann Oncol,2013,24(10):2554-2559.
[4]Loupakis F,Yang D,Yau L,et al.Primary tumor location as a prognostic factor in metastatic colorectal cancer[J].J Natl Cancer Inst,2015,107(3).
[5]Anastasiou D,Poulogiannis G,Asara JM,et al.Inhibition of pyruvate kinase M2by reactive oxygen species contributes to cellular antioxidant responses[J].Scie nce,2011,334(6060):1278-1283.
[6]Azuma M,Shi M,Danenberg KD,et al.Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients[J].Pharmacogenomics,2007,8(12):1705-1713.
[7]Yin C,Jiang C,Liao F,et al.Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer[J].Onco Targets Ther,2014,7:1415-1422.
[8]Zhang CJ,Zhang SY,Zhang CD,et al.Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer:an updated metaanalysis[J].Aging(Albany NY),2018,10(6):1424-1441.
[9]Amadori M,Barone D,Scarpi E,et al.Dynamic contrast-enhanced ultrasonography(D-CEUS)for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer[J].Eur Radiol,2018,28(7):2969-2978.
[10]De Bruyne S,Van Damme N,Smeets P,et al.Value of DCE-MRIand FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases[J].Br JCancer,2012,106(12):1926-1933.
[11]Holch JW,Ricard I,Stintzing S,et al.Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab(FIRE-3 trial)[J].Eur JCancer,2019,106:115-125.
[12]Prager GW,Braemswig KH,Martel A,et al.Baseline carcinoembryonic antigen(CEA)serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer[J].Cancer Sci,2014,105(8):996-1001.